Risk factor
Weak & very vulnerable to price shocks
Profitability factor
Greatly overvalued vs peers
About
MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia;...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is overpriced on P/FCF.
Target Price
The average target price of MEDCL.PA is 33 and suggests 16% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Buy
Sell